DOM-URSODIOL C TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
23-04-2013
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
URSODIOL
Tilgængelig fra:
DOMINION PHARMACAL
ATC-kode:
A05AA02
INN (International Name):
URSODEOXYCHOLIC ACID
Dosering:
250MG
Lægemiddelform:
TABLET
Sammensætning:
URSODIOL 250MG
Indgivelsesvej:
ORAL
Enheder i pakken:
100
Recept type:
Prescription
Terapeutisk område:
CHOLELITHOLYTIC AGENTS
Produkt oversigt:
Active ingredient group (AIG) number: 0122789001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2006-08-10
Produktets egenskaber
PRODUCT MONOGRAPH
PR
DOM-URSODIOL C
Ursodiol Tablets USP
250 mg & 500 mg
CHOLESTATIC LIVER DISEASES
DOMINION PHARMACAL
DATE OF REVISION:
6111 Royalmount Avenue, Suite 100
April 23, 2013
Montreal, Quebec H4P 2T2
CONTROL NUMBER: 163339
_ _
_Dom-URSODIOL C Product Monograph _
_Page 2 of 29_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
INDICATIONS AND CLINICAL USE
....................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE
REACTIONS..........................................................................................................
5
DRUG INTERACTIONS
........................................................................................................
10
DOSAGE AND ADMINISTRATION
....................................................................................
11
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 11
STORAGE AND STABILITY
................................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
.............................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
.....................................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................
14
CLINICAL TRIALS
.....................................................................................................
Læs hele dokumentet
